Pharmaceutical Contract Development and Manufacturing Market Poised for Strong Growth to USD 337.6 Billion by 2031, Fueled by Outsourcing Trends and Biologics Demand

The Global Pharmaceutical Contract Development and Manufacturing Market is estimated at USD 193.9 billion in 2024 and is projected to reach USD 337.6 billion by 2031, growing at a CAGR of 8.0% during the forecast period (2024-2031). This robust growth is driven by the pharmaceutical industry's increasing reliance on outsourcing to enhance R&D efficiency, manage complex manufacturing, and accelerate time-to-market, particularly for high-growth biologic drugs and advanced therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pharmaceutical-contract-development-and-manufacturing-market?jd

North America Key Industry Developments (Largest Market Share)
✅ December 2025: U.S. FDA Issues New Draft Guidance on Continuous Manufacturing for CDMOs. The U.S. Food and Drug Administration (FDA) released updated draft guidance encouraging the adoption of advanced continuous manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs). This regulatory push is aimed at improving drug quality, supply chain resilience, and manufacturing flexibility for both small molecules and biologics.
✅ November 2025: Major North American CDMO Announces Expansion of Viral Vector Manufacturing Capacity. A leading CDMO specializing in cell and gene therapies announced a significant capital investment to double its viral vector manufacturing capacity at a site in North Carolina. This expansion directly targets the soaring demand for lentiviral and adeno-associated virus (AAV) vectors used in next-generation therapies.
✅ October 2025: Strategic Partnership for Integrated mRNA Platform. A top-tier North American CDMO entered into a strategic collaboration with a biotechnology firm to co-develop an integrated platform for mRNA drug substance and lipid nanoparticle (LNP) drug product manufacturing, aiming to capture growth in the mRNA therapeutics and vaccines market.

Asia-Pacific Key Industry Developments (Fastest Growing Region)
✅ December 2025: Japanese CDMO Giant Invests in New High-Potency API (HPAPI) Facility in China. A leading Japanese pharmaceutical services company broke ground on a new, state-of-the-art facility in China dedicated to the highly specialized manufacturing of High-Potency Active Pharmaceutical Ingredients (HPAPIs) for oncology drugs, strengthening its foothold in the region's high-value segment.
✅ November 2025: Indian CDMO Leaders Form Consortium for Advanced Drug Delivery Technologies. Three major Indian CDMOs announced the formation of a strategic consortium to pool R&D resources and manufacturing capabilities for complex injectables and long-acting drug delivery systems, positioning the country as a hub for advanced formulation development.
✅ October 2025: South Korean Government Launches Incentive Program for Biologics CDMOs. The South Korean Ministry of Trade, Industry and Energy unveiled a new financial incentive package to support domestic CDMOs in upgrading their biologics manufacturing capabilities to meet international standards, aiming to boost exports and capture more global market share.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-contract-development-and-manufacturing-market
(Purchase 2 or more Reports and get 50% Discount)

Key Mergers and Acquisitions (2025)
✅ November 2025: Thermo Fisher Scientific Inc. Acquires a Specialized Biologics Analytical Testing Firm. Thermo Fisher Scientific Inc. completed the acquisition of a company renowned for its advanced analytical development and testing services for monoclonal antibodies and other large molecules. This move strengthens Thermo Fisher's integrated value proposition for biologic drug developers.
✅ October 2025: Catalent Expands European Footprint with Fill-Finish Facility Acquisition. Catalent finalized the acquisition of an aseptic fill-finish facility in Eastern Europe from a mid-sized pharmaceutical company. The acquisition provides Catalent with immediate, scaled capacity for sterile vial and syringe filling to serve European and global clients.

Market Segmentation Analysis
-By Service: Biologics Manufacturing Services is the High-Growth Engine
Biologics Manufacturing Services is the fastest-growing service segment, fueled by the rapid expansion of the monoclonal antibodies, cell and gene therapy, and vaccine markets. The complexity and capital intensity of biologics production make outsourcing to specialized CDMOs a preferred strategy for many drug sponsors.
Pharmaceutical Manufacturing Services for small molecules remains the largest volume segment, covering the production of solid oral dosage forms (tablets, capsules) and other conventional pharmaceuticals, driven by the continued demand for generic and branded small molecule drugs.

-By End-User: Large Pharmaceutical Companies are the Core, Small Biotechs Drive Innovation
Large Pharmaceutical Companies are the largest end-user segment, leveraging CDMOs for capacity overflow, specialized technology access, and lifecycle management of mature products, allowing them to focus internal resources on core R&D.
Small and Mid-Sized Pharmaceutical/Biotech Companies are the primary growth drivers for high-value services. These innovators often lack internal manufacturing capabilities and rely entirely on CDMOs to bring their drug candidates from clinical trials to commercial launch, especially for complex biologics.

Growth Drivers:
1. Rising Outsourcing by Pharmaceutical Innovators: Companies are increasingly adopting strategic outsourcing to reduce fixed costs, access specialized expertise, and accelerate drug development timelines, transforming CDMOs from simple suppliers to essential innovation partners.
2. Exponential Growth of the Biologics and Advanced Therapy Pipeline: The booming pipeline of monoclonal antibodies, cell therapies, gene therapies, and mRNA vaccines requires highly specialized and capital-intensive manufacturing, which is predominantly outsourced to CDMOs with the requisite technology.
3. Cost and Efficiency Pressures in Drug Development: The need to control the escalating costs of drug development and commercialization is pushing sponsors of all sizes to leverage the scale and efficiency of CDMOs to optimize their operational expenditures.
4. Increasing Complexity of Manufacturing and Global Supply Chains: The complexity of modern drug manufacturing (e.g., sterile fill-finish, controlled substances) and the need for resilient, multi-regional supply chains make partnerships with global CDMOs a strategic necessity.
5. Patent Cliffs and Growth of Generics/Biosimilars: The expiration of blockbuster drug patents creates massive opportunities for generic and biosimilar production, a market heavily served by CDMOs specializing in efficient, high-volume manufacturing.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pharmaceutical-contract-development-and-manufacturing-market?jd

Regional Insights
North America is the largest market. Its dominance is anchored by the world's highest concentration of innovative biopharmaceutical companies, substantial R&D investment, a strong regulatory framework (FDA), and the presence of many leading global CDMO headquarters.
Asia-Pacific is the fastest-growing market. Expansion is propelled by significant cost advantages, rapid improvements in quality and regulatory compliance, massive investments in biomanufacturing capacity, and supportive government policies in countries like China, India, Singapore, and South Korea.

Key Players:
The key players contributing to the growth of the global market include Lonza Group, Thermo Fisher Scientific Inc., Catalent, Recipharm AB, AbbVie (Contract Manufacturing division), Siegfried Holding AG, Evonik Industries, Boehringer Ingelheim, Piramal Pharma Limited, Fujifilm Healthcare, Asymchem Laboratories (Tianjin) Co., Ltd., and WuXi AppTec.

Key Highlights (Top 5 Key Players):
1. Lonza Group is a global leader, particularly in biologics and cell & gene therapy CDMO services. Its strength lies in its world-class mammalian cell culture capabilities, viral vector manufacturing expertise, and strategic partnerships with top biotech innovators.
2. Thermo Fisher Scientific Inc. (via its Patheon and Pharma Services divisions) is a powerhouse offering integrated, end-to-end solutions from drug substance to finished product. Its competitive edge is its unparalleled scale, global network, and combination of CDMO services with a vast portfolio of analytical instruments and consumables.
3. Catalent is a leading provider of advanced delivery technologies, biologics, and oral dose manufacturing. Its leadership in softgel capsules, blow-fill-seal, and gene therapy manufacturing, combined with a strong focus on patient-centric drug development, makes it a critical partner for complex formulations.
4. WuXi AppTec is a dominant force from China, offering a fully integrated "end-to-end" platform from discovery through manufacturing. Its massive capacity, efficiency, and "follow-the-molecule" strategy have made it an indispensable partner for many global pharmaceutical and biotech companies.
5. Samsung Biologics (while not listed, is a major player) has rapidly emerged as a top-tier pure-play biologics CDMO. Its competitive advantage is massive, state-of-the-art production capacity built to global standards, strategic location in South Korea, and a strong track record in monoclonal antibody manufacturing.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply-Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.